SYSTEMS FOR ADJUSTING ELECTRICAL THERAPY BASED ON IMPEDANCE CHANGES

System and methods for adjusting electrical therapy based on impedance changes are disclosed herein. A method in accordance with a particular embodiment includes applying a therapeutic electrical signal to a patient via an implanted portion of a patient stimulation system that includes a signal delivery device in electrical communication with a target neural population of the patient. The electrical signal is delivered in accordance with a signal delivery parameter having a first value. Using the implanted portion of the patient stimulation system, a change in an impedance of an electrical circuit that includes the signal delivery device is detected. Based at least in part on the detected impedance change, the method can further include automatically adjusting the value of the signal delivery parameter from the first value to a second value different from the first, without human intervention.
TECHNICAL FIELD

[0001] The present disclosure is directed generally to systems and methods for adjusting electrical therapy provided to patients, based on changes in the impedance of circuits providing the therapy, including changes detected while applying therapeutic electrical signals to a patient's spinal cord.

BACKGROUND

[0002] Neurological stimulators have been developed to treat pain, movement disorders, functional disorders, spasticity, cancer, cardiac disorders, and various other medical conditions. Implantable neurological stimulation systems generally have an implantable pulse generator and one or more leads that deliver electrical pulses to neurological tissue or muscle tissue. For example, several neurological stimulation systems for spinal cord stimulation (SCS) have cylindrical leads that include a lead body with a circular cross-sectional shape and one or more conductive rings spaced apart from each other at the distal end of the lead body. The conductive rings operate as individual electrodes and, in many cases, the SCS leads are implanted percutaneously through a large needle inserted into the epidural space, with or without the assistance of a stylet.

[0003] Once implanted, the pulse generator applies electrical pulses to the electrodes, which in turn modify the function of the patient's nervous system, such as by altering the patient's responsiveness to sensory stimuli and/or altering the patient's motor-circuit output. In pain treatment, the pulse generator applies electrical pulses to the electrodes, which in turn can generate sensations that mask or otherwise alter the patient's sensation of pain. For example, in many cases, patients report a tingling or paresthesia that is perceived as more pleasant and/or less uncomfortable than the underlying pain sensation.

[0004] One problem associated with existing stimulation systems is that aspects of the systems and/or the interactions between the systems and the patient may change over time. For example, the impedance of a stimulation circuit (which includes implanted electrodes and the patient's tissue) can change as scar tissue forms at the implant site and/or if the lead moves within the patient, and/or if the lead becomes disconnected or undergoes other changes. As the circuit impedance changes, the strength of the applied signal changes, which can reduce the efficacy of the signal and/or create patient discomfort. Accordingly, there remains a need for improved techniques and systems for addressing patient pain in a manner that is effective and comfortable over an extended period of time.

DETAILED DESCRIPTION

[0006] The present disclosure is directed generally to systems and methods for adjusting electrical therapy parameters based on detected changes in the impedance of an electrical circuit that provides the electrical therapy. Specific details of certain embodiments of the disclosure are described below with reference to adjusting therapy parameters for spinal cord stimulators, which may be used to treat chronic pain. However, the disclosed systems and methods may be used in the context of other stimulators and/or other patient conditions. Accordingly, some embodiments can have configurations, compo-
Overview

During the course of a typical spinal cord stimulation therapy regimen and/or a trial period leading up to the therapy regimen, the impedance of the electrical circuit that provides electrical therapy to the patient may change for any variety of reasons. For example, if the patient changes position and the implanted lead carrying the therapy electrodes shifts, the circuit impedance may change because the electrodes are now adjacent to tissue and/or fluid having different impedance characteristics. If the circuit impedance changes suddenly, the patient may experience a sudden change in the applied current and/or voltage, potentially causing patient discomfort. In other cases, scar tissue may be present at implant and/or build up on the electrodes, decreasing the efficacy with which the electrical signals are provided to the patient. In still other cases, individual electrodes may short together, or the lead may become disconnected or partially disconnected from the signal generator, creating one or more open circuits that reduce or eliminate the efficacy of the therapy. In any of these instances, certain aspects of the following disclosure can automatically detect changes in circuit impedance and automatically respond to the changes in a manner that improves patient comfort and/or improves the efficacy of the therapy.

A method in accordance with a particular embodiment of the disclosure includes applying a therapeutic electrical signal to a patient via an implanted portion of a patient stimulation system that includes a signal delivery device in electrical communication with a target neural population of the patient. The electrical signal is delivered in accordance with one or more signal delivery parameters. The method can further include detecting a change in the impedance of an electrical circuit that includes the signal delivery device, using the implanted portion of the patient stimulation system. Based at least in part on the detected impedance change, the method can still further include automatically adjusting the value of the signal delivery parameter(s) without human intervention. Accordingly, the process of detecting impedance changes and responding to the detected changes can be performed autonomously by the implanted portion of the patient stimulation system.

A method in accordance with another aspect of the disclosure includes automatically identifying changes in the impedance of an electrical circuit that provides therapy to the patient, as a function of time. Based at least upon identifying the changes in impedance as a function of time, the method can further include predicting a future value of the impedance and automatically performing a task based on the predicted future value. Representative tasks include predicting a lead failure, confirming that an identified impedance trend conforms with an expected trend, and/or providing notice to a patient or practitioner of a predicted change in impedance value.

Representative Systems and Methods

In the following discussion, Figures 1A-1B illustrate a representative implementation of a system implanted in the patient's spinal cord region, and Figures 2-6 illustrate representative methods and associated circuits and waveforms for detecting impedance changes and responding to the detected changes. Figure 1A schematically illustrates a representative treatment system 100 for providing relief from chronic pain and/or other conditions, arranged relative to the general anatomy of a patient's spinal cord 191. The system 100 can include a pulse generator 101, which may be implanted subcutaneously within a patient 190 and coupled to a signal delivery element 109. In a representative example, the signal delivery element 109 includes a lead or lead body 110 that carries features or elements for delivering therapy to the patient 190 after implantation. The pulse generator 101 can be connected directly to the lead body 110, or it can be coupled to the lead body 110 via a communication link 102 (e.g., an extension). As used herein, the terms lead and lead body include any of a number of suitable substrates and/or support members that carry devices for providing therapy signals to the patient 190. For example, the lead body 110 can include one or more electrodes or electrical contacts that direct electrical signals into the patient's tissue, such as to provide for patient relief. In other embodiments, the signal delivery element 109 can include devices other than a lead body (e.g., a paddle) that also direct electrical signals and/or other types of signals to the patient 190.

The pulse generator 101 can transmit signals to the signal delivery element 109 that up-regulate (e.g., stimulate or excite) and/or down-regulate (e.g., block or suppress) target nerves. As used herein, and unless otherwise noted, the terms "stimulate" and "stimulation" refer generally to signals that have either type of effect on the target nerves. The pulse generator 101 can include a machine-readable (e.g., computer-readable) medium containing instructions for generating and transmitting suitable therapy signals. The pulse generator 101 and/or other elements of the system 100 can include one or more processors 107, memories 108 and/or input/output devices. Accordingly, the process of determining impedance and taking follow-up action can be performed by computer-executable instructions contained on computer-readable media, e.g., the processor(s) 107 and/or memory(s) 108. The pulse generator 101 can include multiple portions, elements, and/or subsystems (e.g., for directing signals in accordance with multiple signal de-
livery parameters), housed in a single housing, as shown in Figure 1A, or in multiple housings. In any of these embodiments, the pulse generator 101 and/or other implanted components of the system 100 can include elements for detecting and responding to impedance changes.

In some embodiments, the pulse generator 101 can obtain power to generate the therapy signals from an external power source 103. The external power source 103 can transmit power to the implanted pulse generator 101 using electromagnetic induction (e.g., RF signals). For example, the external power source 103 can include an external coil 104 that communicates with a corresponding internal coil (not shown) within the implantable pulse generator 101. The external power source 103 can be portable for ease of use.

In another embodiment, the pulse generator 101 can obtain the power to generate therapy signals from an internal power source, in addition to or in lieu of the external power source 103. For example, the implanted pulse generator 101 can include a non-rechargeable battery or a rechargeable battery to provide such power. When the internal power source includes a rechargeable battery, the external power source 103 can be used to recharge the battery. The external power source 103 can in turn be recharged from a suitable power source (e.g., conventional wall power).

In some cases, an external programmer 105 (e.g., a trial stimulator) can be coupled to the signal delivery element 109 during an initial implant procedure, prior to implanting the pulse generator 101. For example, a practitioner (e.g., a physician and/or a company representative) can use the external programmer 105 to vary the stimulation parameters provided to the signal delivery element 109 in real time, and select optimal or particularly efficacious parameters. During this process, the practitioner can also vary the position of the signal delivery element 109. After the position of the signal delivery element 109 and appropriate signal delivery parameters are established using the external programmer 105, the patient 190 can receive therapy via signals generated by the external programmer 105, generally for a limited period of time. In a representative application, the patient 190 receives such therapy for one week. Assuming the trial therapy is effective or shows the promise of being effective, the practitioner then replaces the external programmer 105 with the implanted pulse generator 101, and programs the pulse generator 101 with parameters selected based on the experience gained during the trial period. Optionally, the practitioner can also replace the signal delivery element 109. Once the implantable pulse generator 101 has been positioned within the patient 190, the signal delivery parameters provided by the pulse generator 101 can still be updated remotely via a wireless physician’s programmer (e.g., a physician’s remote) 111 and/or a wireless patient programmer 106 (e.g., a patient remote). Generally, the patient 190 has control over fewer parameters than does the practitioner. For example, the capability of the patient programmer 106 may be limited to starting and/or stopping the pulse generator 101, and/or adjusting stimulation amplitude.

In any of the foregoing embodiments, the parameters in accordance with which the pulse generator 101 provides signals can be modulated during portions of the therapy regimen. For example, the frequency, amplitude, pulse width, duty cycle, and/or signal delivery location can be modulated in accordance with a preset program, patient and/or physician inputs, and/or in a random or pseudorandom manner. Such parameter variations can be used to address a number of potential clinical situations, including changes in the patient’s perception of pain, changes in the preferred target neural population, and/or patient accommodation or habituation. Such parameter changes can also be implemented automatically to account for detected impedance changes.

Figure 1B illustrates a representative lead 110 that can be connected to the pulse generator 101. The lead 110 can have any suitable number of contacts C positioned along its length L for delivering electrical therapy to the patient. For purposes of illustration, 11 contacts C, identified individually as contacts C1, C2 ... C11 are shown in Figure 1B. In operation, one or more of the contacts C is cathodic and another one or more of the contacts C is anodic. The contacts C can be individually addressable so that any contact C or combination of contacts C can operate as a cathode, and any contact C or combination of contacts C can operate as an anode. The contacts C can be electrically grouped in any of a wide variety of combinations, and individual contacts C can perform different functions (e.g., cathodic functions and/or anodic functions) at different times during the course of a therapy regimen. In any of these embodiments, each contact C may be coupled with a corresponding conductor 111 to the pulse generator 101. The conductors 111 may have one or more connection points along their lengths (e.g., at a junction with the pulse generator 101, and optionally at a junction with an extension). Accordingly, the circuit for a given pair of contacts C includes the contacts C, the patient tissue T between the contacts, the individual conductors 111, connection points along the conductors 111, and connection points between the conductors 111 and the pulse generator 101. As discussed below, aspects of the present disclosure are directed to detecting changes in the overall circuit impedance that may result from changes at any of a variety of points along the circuit, and providing an appropriate response.

Figure 2 illustrates an overall process 220 in accordance with a particular embodiment of the disclosure. The process 220 includes applying electrical therapy to a patient via an implanted or partially implanted system (process portion 225). During the course of the therapy, the process 220 can further include detecting a change in the impedance of an electrical circuit that provides the therapy, using the implanted portion of the system (process portion 226). Based on the detected impedance change, the process 220 can still further include
automatically adjusting signal delivery parameters in accordance with which the therapy is provided, without human intervention (process portion 227). The signal delivery parameters can include signal strength, the location and/or number of electrical contacts delivering therapy to the patient, and/or other parameters. Figure 3 describes further aspects of particular embodiments of the foregoing process.

[0018] Figure 3 is a block diagram illustrating in further detail aspects of the overall process 220 described above with reference to Figure 2. Process portion 221 includes identifying a target neural population. For example, process portion 221 can include identifying one or more neural populations at particular vertebral locations along the patient’s spine. Process portion 222 includes implanting an electrical therapy system, for example, implanting the signal delivery element 109 and the pulse generator 101 described above with reference to Figures 1A and 1B. As discussed above with reference to Figure 1B, the electrical therapy system includes at least one electrical therapy circuit which has associated with it an initial impedance value. In process portion 225, electrical therapy is applied to the patient via the implanted system with the initial impedance value. The impedance value may change over time, which is detected in process portion 226. The electrical therapy signals are typically time-varying signals (e.g., pulses), and the associated circuit can include capacitive and/or resistive elements. Accordingly, the detected impedance can include capacitive and/or resistive components. In particular embodiments, the system can distinguish between resistive and capacitive components of the overall impedance, and use this information to select the appropriate signal delivery parameter to vary. For example, if the impedance change is primarily capacitive, changing the signal delivery frequency may have a greater effect than if the impedance change is primarily resistive.

[0019] The change in impedance of the electrical circuit can be detected by detecting a change in power applied to the circuit (process portion 227), a change in voltage at one or more points along the circuit (process portion 228), a change in current passing through the circuit (process portion 229), and/or changes in other values. In a particular embodiment (process portion 230), the impedance of the electrical therapy circuit is detected while the therapy signal is delivered, for example, by sampling the therapy signal itself. In other embodiments, a dedicated electrical signal can be applied to the electrical therapy circuit and sampled, so as to detect impedance and/or impedance changes, independent of the therapy signal (process portion 231). Accordingly, this arrangement can be used to detect impedance and/or impedance changes of a therapy circuit without the need for the therapy signal to be active on the circuit at that time.

[0020] In any of the foregoing embodiments, the process 220 can include different steps depending upon the magnitude and/or direction of the impedance change. In a particular embodiment, process portion 232 can include determining whether the impedance change is an increase or a decrease. If the change is an increase, process portion 233 can include determining whether the circuit is open. An open circuit can be indicated by an infinite impedance, or by an impedance or impedance increase that exceeds a suitable threshold value.

[0021] Process portions 234-240 may be performed if, in process portion 233, it is determined that the electrical therapy circuit is open. For example, process portion 234 can include reducing the signal strength (e.g., the applied current and/or voltage) prior to closing or attempting to close the open circuit (process portion 235). In particular embodiments, process portion 234 can include reducing the signal strength to zero, or to a suitable non-zero value such that when the circuit is later closed, the patient does not receive an uncomfortable sensation. Process portion 235 can, for example, include changing one or more of the contacts (e.g., those shown in Figure 1B) that form a portion of the electrical therapy circuit. This change can be achieved by opening and closing appropriate switches at the pulse generator 101. Once the change has been made, process portion 236 can include gradually increasing the strength of the signal applied to the therapy circuit. By first reducing the signal strength (process portion 234) and then gradually increasing the signal strength after the change in the circuit has been made (process portion 236), the process 220 can avoid subjecting the patient to a sudden increase in the applied signal, which may cause patient discomfort.

[0022] Once the signal strength has been increased, process portion 237 can include checking the impedance to determine whether it has returned to its original level, or has otherwise achieved an acceptable level. This process can include checking the power, voltage, and/or current, as described above with reference to process portions 227-229. If the impedance is at an acceptable level, process portion 238 includes continuing to deliver the therapy. In addition, the patient and/or practitioner can be notified that a change has been made to account for the detected increase in impedance. The notification can take any of a variety of suitable forms, including a vibratory signal, and/or an internally stored signal that is downloaded external to the patient during a battery recharge operation or diagnostic operation. If the change did not result in an adequately improved impedance level, then in process portion 239, the system checks to determine whether all the contacts of the implanted lead have been checked. If not, the process returns to process portion 234 and a different contact is placed in the circuit. If, after all of the contacts have been checked and determined to form an open circuit, this can indicate that the lead is disconnected, which is flagged for the user and/or practitioner in process portion 240, using any suitable notification technique. In process portion 250, the system checks for lead reconnection, e.g., by rechecking all contacts for an open circuit. Once the lead has been reconnected, the system returns to process portion 236 so as to gradually increase signal strength.
If in process portions 232 and 233, the system determines that the impedance has decreased, or has increased but not so much as to indicate an open circuit, then in process portion 241, the signal delivery parameters are adjusted in an autonomous manner to bring the impedance values to acceptable levels. Process portion 241 can in turn include changing any of a variety of signal delivery parameters as identified by process portions 242-245. For example, process portion 242 can include changing the number of active contacts in the electrical therapy circuit. The number of active contacts may be increased in particular embodiments if the circuit impedance increases (e.g., to provide parallel electrical paths), and may be decreased in other embodiments if the impedance decreases. In a particular example, the patient may change position or the lead may change position relative to the patient such that the circuit impedance increases because the active contacts are now positioned adjacent to a portion of the patient tissue having a higher impedance. By increasing the number of active contacts, the resulting circuit can include portions of the patient tissue having a lower impedance. Of course, when such a change is made, it is made so that the resulting therapy is still applied to the appropriate portion of the patient tissue, even though the range over which the active contacts are positioned and may now be expanded. For example, only a subset of the contacts shown in Figure 1B may be used and/or available for such a change, so as to avoid directing the therapy signal too far from the originally intended neural population.

In other embodiments, the system can automatically detect a decrease in the impedance of the therapy circuit. For example, if the lead shifts to a location within the patient that results in a lowered impedance, the system can automatically detect this occurrence. One such example is if the lead shifts from an initial position so as to be in closer proximity to cerebral spinal fluid, which has a relatively low impedance. In such instances, the number of electrical contacts applying the therapy may be decreased. In any of the foregoing embodiments once the responsive change has been made, the process can continue with process portion 251, which includes determining whether the new circuit produces a target impedance value. If so, then in process portion 238, the system delivers additional therapy. In addition, the system can notify the patient and/or practitioner of the update. If the change has not produced a target impedance value, the process returns to process portion 241. At that point, process portion 242 can be re-executed using a different combination of electrodes, or any of process portions 243-245 can be executed.

Process portion 243 includes changing the contacts that are active, for example, without increasing or decreasing the number of active contacts. In a particular example, process portion 243 can include substituting one contact for another. The substituted contact can be an anodic contact or a cathodic contact, and in some embodiments, both anodic and cathodic contacts can be changed. Once the contacts have been changed, the impedance is checked (process portion 251) and the process continues in a manner generally similar to that discussed above.

Process portion 244 includes adjusting the signal strength (increasing or decreasing the strength) in response to an indication that an impedance has changed. The signal strength can correspond to a voltage level, a current level, and/or a power level. Process portion 244 can in turn include selecting an updated strength value (e.g., an updated voltage value or current value) as shown in process portion 252, and then determining whether the updated strength value exceeds a predetermined compliance value (process portion 246). For example, a typical constant current source provides signals at a constant current by modulating the applied voltage, but keeping the applied voltage below a predetermined compliance voltage value, e.g., a programmed compliance voltage. If the selected updated strength value does not result in the compliance value being exceeded, then the impedance can optionally be rechecked in process portion 251 and the system can then deliver additional therapy (process portion 238). The impedance check at process portion 251 may be optional in this case because changing the signal strength may not change impedance.

If, in process portion 246 it is determined that the compliance value is exceeded by the selected updated strength value, then in process portion 247, the compliance value is adjusted. As discussed above, a constant current source automatically adjusts the applied voltage to account for at least some changes in the circuit impedance, so as to effectively produce a constant current. If the circuit impedance increases beyond a level that can be accommodated by a voltage change that remains within the maximum compliance voltage value, the compliance voltage can be adjusted, within preset limits that are established to provide for patient safety and comfort. Accordingly, in process portion 248, the system determines whether such a preset limit on the degree to which the compliance voltage can be adjusted has been exceeded. If it has not, then the impedance can optionally be checked (process portion 251) and the therapy delivered to the patient (process portion 238). If the necessary compliance value exceeds the preset limit, then in process portion 249, the user and/or the practitioner can be notified that the recommended signal strength is not available without exceeding preset limits on the amount by which the compliance value can be changed. In addition to or in lieu of providing such notification, the process can automatically revert to one of the other available methods for adjusting the signal delivery parameters, including process portion 242 (changing the number of active contacts), process portion 243 (changing which contacts are active), and/or process portion 245 (changing other parameters). The other parameters that may be changed can include, but are not limited to, frequency, pulse width, and/or duty cycle.

In some embodiments, the compliance voltage
value is increased, e.g., to account for an increased circuit impedance. In other embodiments, the compliance voltage value is decreased, e.g., in response to an impedance reduction. In any of the foregoing embodiments, it can be advantageous to keep the compliance value as low as possible, while still providing signals at an effective signal strength, so as to reduce the power consumed by the system. Accordingly, the system can automatically adjust the compliance margin (e.g., the difference between the compliance voltage and actual delivered voltage). For example, the system can automatically set the compliance margin to be a fixed level (in volts or millivolts) above the actual delivered voltage (e.g., the updated strength value). In other embodiments, the compliance margin can be a fixed percentage of the updated strength value. In still further embodiments, the compliance margin can vary, and can be automatically adjusted based on the range of requested strength perturbations, e.g., the degree to which the updated strength values deviate from the strength value being applied at that time. If the range is wide, the compliance margin can correspondingly be increased to avoid having to repeatedly adjust the compliance value. If the range is narrow, the compliance margin can be correspondingly be narrowed to reduce power consumption. Accordingly, in particular embodiments, the system can automatically track the foregoing perturbations and automatically adjust the compliance margin.

In particular instances, the foregoing arrangement can track the gradual reduction in the range of impedance perturbations that result when a newly implanted lead becomes "scarred in." The system can also track increases in the range of impedance perturbations if the scar tissue continues to build up in a manner that requires frequent upward adjustments in signal strength, and/or if the lead and/or patient undergo other changes that affect circuit impedance.

The systems and methods described above can operate in accordance with a variety of different modes. For example, during a first mode of operation, the system can check the impedance of one or more circuits that include only active therapy contacts. If, during the first mode of operation, the system identifies an impedance change in association with the active contact(s), it can then check the impedance of inactive contacts during a second mode of operation. Based on the impedance measurements obtained during the second mode, the system can automatically change which contacts are active and which are inactive. This arrangement can reduce the time and power required to perform an impedance check because inactive contacts are checked only when an impedance change is identified in association with one or more active contacts.

One feature of several embodiments described herein is that the system 100 can automatically identify changes in impedance via an implanted portion of the system, and automatically take appropriate action without patient or practitioner intervention. An advantage of this feature is that the system need not rely on external analysis and/or diagnostics, and accordingly can implement the action more quickly and/or more conveniently.

Another feature of several of the embodiments described herein is that the system 100 can automatically identify an open circuit (e.g., a disconnected lead) and then gradually increase the strength of the applied therapy signal once the open circuit has been closed. An advantage of this feature is that it can reduce or eliminate the likelihood for the patient to feel a sudden shock or discomfort, which may otherwise result when the therapy signal is suddenly re-applied at the target strength value.

Still another feature of several of the embodiments described herein is that the system 100 can automatically adjust a preset compliance level (e.g., a voltage or current) to account for impedance changes. While increasing the compliance level may reduce overall system efficiency (e.g., may result in an increased power consumption), the patient can receive dynamically updated and effective therapy in a short period of time. This arrangement can allow the patient to continue receiving effective therapy until the power source is recharged or replaced, as opposed to potentially requiring that the patient undergo an in-office procedure to address the source of the impedance change (e.g., lead movement or scar tissue).

Yet another feature of several of the disclosed embodiments is that the system can detect impedance changes while the patient is receiving therapy. Accordingly, the patient's therapy need not be interrupted to provide this function. In addition, the system can not only check the impedance of the lead contacts applying therapy at a given time, but also other contacts. Accordingly, the system can readily identify alternate contacts that may be substituted for or provided in addition to the currently active contacts, to address changes in impedance. In addition, this arrangement allows the system to rapidly identify conditions that may affect contacts other than just the currently active contacts. Such conditions include a disconnected lead.

Figure 4A is a schematic illustration of portions of the system 100 used for impedance detection in accordance with an embodiment of the disclosure. The system 100 can include an impedance detector 119 that in turn includes a microcontroller or microprocessor 107 that is coupled to an analog-to-digital (A/D) converter 112. The A/D converter 112 is coupled to a stimulation circuit 113 that includes one or more electrical contacts, and is implanted in the patient 190. Accordingly, the A/D converter 112 converts analog signals (e.g., voltage and/or current levels) to digital values, which are analyzed by the microprocessor 107 to identify impedance changes.

Figure 4B is a representative circuit diagram of an embodiment of the system 100 described above with reference to Figures 1 and 4A. In this particular embodiment, the A/D converter 112 is connected to a voltage divider 114, which is in turn selectively coupleable to the stimulation circuit 113 via an enable measurement switch.
In any of the foregoing embodiments, the skill in the relevant art.

In figures 2 and 3.

The microprocessor 107 that automatically identifies changes in the impedance of an electrical circuit can include an amplifier. In any of these embodiments, the amplification circuit 113 can include a constant current source 116 that receives a compliance voltage input 117, which can be set to initial preset limits, as discussed above. The constant current source 116 can be coupled to a contact selector 118, which is in turn connected to the contacts C1, C2, ..., C11 positioned at the patient 190. The contact selector 118 can include any of a variety of suitable switching devices to select one or more of the contacts C1-C11 for applying therapy to the patient, and/or for impedance detection. The circuit can include an H-bridge or other suitable element to selectively reverse the current direction for one or more combinations of contacts C. In other embodiments, the system 100 can include other suitable arrangements, for example, a constant voltage source rather than a constant current source, a current sink in addition to the constant current source, and/or other suitable arrangements known to those of ordinary skill in the relevant art.

In any of the foregoing embodiments, the detector 119 will typically detect the impedance of a circuit that includes at least two contact, e.g., C1 and C2. If the circuit impedance increases beyond a preset threshold, the system can automatically step through the remaining contacts, e.g., C1 in combination with C3, C1 in combination with C4, and so on. This sequential process can be completed for any combination of contacts that may be suitable for continuing the patient therapy. In any of these cases, however, the impedance of the tested circuit will include the impedances of all the contacts in the circuit. Accordingly, the microprocessor 107 can include one or more of a variety of provisions for isolating impedance changes to a particular contact or contacts. For example, in one case, a nominal impedance can be assigned to other contacts included in the circuit (e.g., if multiple contacts are coupled in parallel in the circuit), and then subtracted from a total impedance to obtain the impedance for a given contact. In another embodiment, a series of multivariable equations can be used to solve for the impedance of each individual contact. Such an implementation is expected to consume more power than others, and accordingly, may in at least some embodiments be selected only when suitable power is available.

In another approach, the microprocessor 107 can employ a successive approximation technique by using an initially measured value for one contact to estimate values for other contacts, and then repeating the process as the impedances of circuits with other contacts are identified. In any of the foregoing embodiments, the detector 119 obtains impedance values and/or changes in impedance values which are provided as inputs to other functional elements of the microprocessor 107 that automatically implement the changes described above with reference to Figures 2 and 3.

Figure 5A illustrates a representative waveform 570a having multiple pulses 571, each with a cathodic phase 572 and an anodic phase 573 for delivering therapy to the patient. In a particular aspect of this embodiment, the waveform 570a can be sampled directly (e.g., at the cathodic phase 572) via the circuit described above with reference to Figure 4B, to identify circuit impedance. For example, arrow S identifies a suitable sampling point. In particular embodiments, the waveform 570a can be sampled at multiple points, and the results analyzed to provide a complex impedance value.

Figure 5B illustrates another waveform 570b having multiple bursts of pulses 571 separated by a quiescent period. In this embodiment, a separate detection pulse 574 can be superimposed on the waveform 570b at the quiescent period. The impedance characteristics of the circuit are accordingly determined by analyzing the impedance associated with the detection pulse 574. In still further embodiments, the detection pulse 574 can be applied to a circuit that is not applying therapy at that time, in which case the waveform 570b is entirely quiescent except for the presence of the detection pulse 574. In any of these embodiments, the detection pulse 574 is typically provided at subthreshold leads to avoid triggering a motor and/or sensory response in the patient.

In any of the foregoing embodiments, the therapy signal can be applied at frequencies ranging from about 1.5 kHz to about 100 kHz, duty cycles of from about 50% to about 100%, e.g., with the stimulation signal on for a period of about 10 milliseconds to about 2 milliseconds, and off for a period of about 1 millisecond to about 1.5 milliseconds. The applied pulses can have a width from about 30 to 35 microseconds and an amplitude in the range of about 1 mA to about 4 mA. Other representative parameters are included in co-pending U.S. Provisional Application No. 61/176,868, incorporated herein by reference. In other embodiments, these parameters can have different values suitable for providing patient therapy to any of a variety of neural populations to address any of a variety of patient conditions.

Figure 6 is a flow diagram illustrating a process 620 in accordance with another embodiment of the disclosure. Process 620 can include applying electrical therapy to the patient (process portion 625), and automatically identifying changes in the impedance of an electrical circuit via which the therapy is applied, as a function of time (process portion 626). Based on the information obtained in process portion 626, process portion 627 can include predicting a future value of the impedance. For example, the future value can be predicted by a suitable extrapolation technique, including a linear or higher order function, a least-squares curve fit, or other techniques. Based on the predicted future value of the impedance, process portion 628 can include automatically performing a task, e.g., without human intervention. Representative tasks can include predicting a lead failure, e.g., if the lead impedance intermittently becomes excessive.

In other embodiments, process portion 628 can include predicting excessive impedance such as may result from
From the foregoing, it will be appreciated that any of the foregoing activities, for example, if the impedance exhibits a steady growth. Still another function that may be performed via process portion 628 includes confirming that the impedance trend identified in process portion 626 conforms with an expected trend, and/or adjusting the compliance values and/or compliance margins, as discussed above. In any of these embodiments, process portion 628 can include notifying the patient and/or practitioner, alone or in combination with any of the foregoing activities.

Representative features

The representative features set out in the following clauses stand alone or may be combined, in any combination, with one or more features disclosed in the text and/or drawings of the specification.

1. A method for controlling a patient therapy device, comprising:
   
   applying a therapeutic electrical signal to a patient via an implanted portion of a patient stimulation system that includes a signal delivery device in electrical communication with a target neural population of the patient, the electrical signal being delivered in accordance with a signal delivery parameter having a first value;
   
   using the implanted portion of the patient stimulation system, detecting a change in an impedance of an electrical circuit that includes the signal delivery device; and
   
   based at least in part on the detected impedance change, automatically adjusting the value of the signal delivery parameter from the first value to a second value different than the first value, without human intervention.

2. The method of clause 1 wherein automatically adjusting the value of the signal delivery parameter includes halting delivery of the electrical signal.

3. The method of clause 1 wherein automatically adjusting the value of the signal delivery parameter includes changing at least one of a strength, pulse width, and duty cycle of the signal.

4. The method of clause 1 wherein the electrical signal is applied to a first contact set, and wherein automatically adjusting the value of the signal delivery parameter includes applying the electrical signal to a second contact set having a different member than the first contact set.

5. The method of clause 1 wherein detecting a change in an impedance of an electrical circuit includes detecting a change in an impedance of an electrical circuit that includes the target neural population.

6. The method of clause 1 wherein applying a therapeutic electrical signal includes applying the electrical signal via an implanted electrical contact carried by the signal delivery device and exposed to the patient's tissue.

7. The method of clause 1 wherein applying a therapeutic electrical signal includes applying the signal to the patient's spinal cord region.

8. The method of clause 1 wherein detecting a change in an impedance includes detecting an increase in impedance.
9. The method of clause 8 wherein automatically adjusting the value of the signal delivery parameter includes increasing a number of implanted electrical contacts to which the electrical signal is directed.

10. The method of clause 8 wherein the electrical signal is applied to a first implanted electrical contact set, and wherein automatically adjusting the value of the signal delivery parameter includes applying the electrical signal to a second implanted electrical contact set having different members than the first contact set.

11. The method of clause 8 wherein automatically adjusting the value of the signal delivery parameter includes increasing a strength of the signal.

12. The method of clause 8 wherein the implanted portion of the stimulation system includes a constant current source having a compliance voltage level with a first value, and wherein automatically adjusting the value of the signal delivery parameter includes:

   increasing the compliance voltage level from the first value to a second value higher than the first;

   and

   increasing a strength of the signal beyond a strength available with the first value.

13. The method of clause 8 wherein detecting an increase in an impedance includes detecting an increase correlated with an increase in power provided to the signal delivery device.

14. The method of clause 8 wherein detecting an increase in an impedance includes detecting an open circuit.

15. The method of clause 14 wherein automatically adjusting a signal delivery parameter includes automatically adjusting a compliance value in accordance with which the electrical signal is delivered, in response to the detected impedance change.

16. The method of clause 1 wherein detecting a change in an impedance includes detecting a decrease in impedance.

17. The method of clause 16 wherein automatically adjusting the value of the signal delivery parameter includes decreasing a strength of the electrical signal.

18. The method of clause 16 wherein detecting a decrease includes detecting a decrease caused by proximity of the electrical contacts of the signal delivery device to cerebral spinal fluid.

19. The method of clause 16 wherein detecting a decrease includes detecting a decrease caused by an electrical short between electrical contacts of the signal delivery device.

20. The method of clause 1 wherein detecting a change in an impedance includes detecting a change in impedance resulting from a build up of scar tissue on the signal delivery device.

21. The method of clause 1 wherein detecting a change in an impedance includes detecting a change in impedance resulting from a change in position of the signal delivery device relative to the patient.

22. The method of clause 1 wherein detecting a change in an impedance includes detecting a change in impedance resulting from change in the patient’s posture.

23. The method of clause 1 wherein detecting a change in an impedance includes detecting a change in impedance as a function of time and wherein the method further comprises establishing a trend for future changes in impedance.

24. The method of clause 1 wherein detecting a change in an impedance includes detecting a change in impedance by monitoring the therapeutic electrical signal.

25. The method of clause 1 wherein detecting a change in an impedance includes applying an electrical signal in addition to the therapeutic electrical signal and detecting a change in impedance by monitoring the additional electrical signal.

26. The method of clause 1 wherein automatically adjusting a signal delivery parameter includes automatically adjusting a compliance margin in accordance with which the electrical signal is delivered, in response to the detected impedance change.

27. The method of clause 1 wherein automatically adjusting a signal delivery parameter includes automatically adjusting a compliance value in accordance with which the electrical signal is delivered, in response to the detected impedance change.

28. A method for controlling a patient therapy device, comprising:

   applying a therapeutic electrical signal to a patient via a patient stimulation system that includes a signal delivery electrical contact in electrical communication with a target neural population of the patient, the electrical signal having
a signal delivery parameter with a first value;  
amtically identifying changes in an imped-
ance of an electrical circuit that includes the sig-
ental delivery electrical contact, as a function of
time;  
5  
Based at least in part on identifying the changes
in impedance as a function of time, predicting a
future value of the impedance; and
based at least in part on the predicted future
value of the impedance, automatically perform-
ing a task.

29. The method of clause 28 wherein automatically
performing a task includes automatically comparing
the identified changes in impedance as a function of
time with a target rate of impedance change.

30. The method of clause 28 wherein automatically
performing a task includes automatically adjusting
the value of the signal delivery parameter from the
first value to a second value different than the first
value, without human intervention.

31. The method of clause 28 wherein automatically
performing a task includes: automatically adjusting
the value of the signal delivery parameter from the
first value to a second value different than the first
value, without human intervention; and
applying a second therapeutic electrical signal to the
patient using the second value of the signal delivery
parameter.

32. The method of clause 28 wherein automatically
identifying changes in an impedance as a function
of time includes automatically identifying the chang-
es as a function of time using a portion of the patient
stimulation system that is implanted in the patient,
without human intervention.

33. The method of clause 28 wherein automatically
identifying changes in an impedance as a function
of time includes automatically identifying the chang-
es as a function of time using a portion of the patient
stimulation system that is external to the patient.

34. The method of clause 28 wherein predicting a
future value of the impedance includes extrapolating
the future value based on past values.

35. A patient therapy system, comprising:

- a patient-implantable portion that includes a
  pulse generator and a signal delivery device
  having an electrical contact positioned to be in
electrical communication with a target neural
population of a patient when implanted;
an impedance detector carried by the implanta-
ble portion, the impedance detector being oper-
5
atively coupled to an electrical circuit that in-
cludes the electrode to detect an impedance of
the electrical circuit; and a processor carried by
the patient-implantable portion, the processor
having a computer-readable medium pro-
grammed with instructions that, when executed:

receive an indication of an impedance
change from the impedance detector; and
based at least in part on the detected im-
pedance change and without human inter-
vention, automatically adjust a value of a
signal delivery parameter in accordance
with which the patient-implantable portion
delivers an electrical signal to the electrical
contact.

36. The system of clause 35 wherein the processor
is programmed with instructions that, when execut-
ed, automatically adjust an amplitude of the electrical
signal.

37. The system of clause 35 wherein the processor
is programmed with instructions that, when execut-
ed, automatically terminate the electrical signal.

38. The system of clause 35 wherein the electrical
signal is applied to a first contact set, and wherein
automatically adjusting the value of the signal deliv-
ery parameter includes applying the electrical signal
to a second contact set having a different member
than the first contact set.

39. The system of clause 35 wherein the implantable
portion includes a constant current source having a
compliance voltage level with a first value, and
wherein automatically adjusting the value of the sig-
nal delivery parameter includes:

increasing the compliance voltage level from the
first value to a second value higher than the first; and
increasing a strength of the signal beyond a
strength available with the first value.

40. The system of clause 35 wherein the implantable
portion includes a constant current source having a
compliance voltage level with a first value, and
wherein automatically adjusting the value of the sig-
nal delivery parameter includes decreasing the com-
pliance level from the first value to a second value
less than the first value.

41. The system of clause 35 wherein receiving an
indication of an impedance change includes receiv-
ing an indication of an open circuit.

42. The system of clause 41 wherein automatically
adjusting the value of the signal delivery parameter includes reducing a strength of the electrical signal and then ramping up the strength of the electrical signal after the circuit is closed.

43. The system of clause 35 wherein the pulse generator outputs a therapeutic electrical signal and a diagnostic signal, and wherein the impedance detector is coupled to the electrical circuit to detect a characteristic of a diagnostic electrical signal.

44. The system of clause 35 wherein automatically adjusting a value of a signal delivery parameter includes automatically adjusting at least one of a compliance value and a compliance margin in accordance with which the electrical signal is delivered.

45. A patient therapy system, comprising:

- a patient-implantable portion that includes a pulse generator and a signal delivery device having an electrode positioned to be in electrical communication with a target neural population of a patient when implanted;
- an impedance detector operatively coupled to an electrical circuit that includes the electrode to detect an impedance of the electrical circuit;
- and a processor having a computer-readable medium programmed with instructions that when executed:

  - automatically identify changes in the impedance of the electrical circuit as a function of time;
  - based at least in part on identifying the changes in impedance as a function of time, predict a future value of the impedance; and
  - based at least in part on the predicted future value of the impedance, automatically perform a task.

46. The system of clause 45 wherein the processor is carried by the patient-implantable pulse generator.

47. The system of clause 45 wherein automatically performing a task includes comparing the identified impedance changes with a predetermined schedule of impedance changes.

48. The system of clause 45 wherein automatically performing a task includes automatically issuing a notification.

49. The system of clause 45 wherein identifying changes in impedance includes identifying intermittent impedance increases, and wherein predicting a future value of the impedance includes predicting a failure of the signal delivery device.

50. The system of clause 45 wherein the instructions, when executed:

  - receive an indication of an impedance change from the impedance detector; and
  - based at least in part on the detected impedance change and without human intervention, automatically adjust a value of a signal delivery parameter(s) in accordance with which the patient-implantable portion delivers an electrical signal to the electrical contact.

51. The system of claim 6 wherein the instructions, when executed:
executed:

determine if the electrical signal exceeds a predetermined compliance voltage value; and if it is determined that the predetermined compliance voltage value is exceeded, adjust the compliance voltage value.

8. The system of claim 6 wherein the instructions, when executed, automatically adjust an amplitude of the electrical signal.

9. The system of claim 6 wherein the instructions, when executed, automatically terminate the electrical signal.

10. The system of claim 6 wherein the electrical signal is applied to a first contact set, and wherein automatically adjusting the value of the signal delivery parameter(s) includes applying the electrical signal to a second contact set having a different member than the first contact set.

11. The system of claim 6 wherein the implantable portion includes a constant current source having a compliance voltage level with a first value, and wherein automatically adjusting the value of the signal delivery parameter(s) includes:

   increasing the compliance voltage level from the first value to a second value higher than the first value; and
   increasing a strength of the signal beyond a strength available with the first value.

12. The system of claim 6 wherein the implantable portion includes a constant current source having a compliance voltage level with a first value, and wherein automatically adjusting the value of the signal delivery parameter(s) includes decreasing the compliance level from the first value to a second value less than the first value.

13. The system of claim 6 wherein receiving an indication of an impedance change includes receiving an indication of an open circuit.

14. The system of claim 1 wherein:

   the future value of the impedance is predicted using an extrapolation technique,
   the patient-implantable portion is configured to deliver an electrical signal having one or more signal delivery parameter(s), and automatically performing a task includes updating one or more of the signal delivery parameters.
FIG. 2

220

Apply electrical therapy to patient via implanted system

225

Detect change in impedance of electrical circuit using implanted portion of system

226

Based on detected impedance, automatically adjust signal delivery parameter without human intervention

227
FIG. 3
FIG. 6

620

625

Apply electrical therapy to patient

626

Automatically identify changes in impedance of electrical therapy circuit, as a function of time

627

Predict a future value of the impedance

628

Based on predicted future impedance value, automatically perform a task
# DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>* abstract; figures 1-8 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* paragraphs [0034] - [0037] *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* paragraphs [0043] - [0045] *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* paragraphs [0070] - [0077] *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* abstract; figures 1-8 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* page 23, line 6 - line 19 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* pages 41-45 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* abstract; figures 1-10 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* paragraphs [0009] - [0013] *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* paragraphs [0033] - [0035] *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* paragraphs [0044] - [0055] *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* paragraphs [0067] - [0068] *</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>* the whole document *</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims.

Place of search: Munich
Date of completion of the search: 6 December 2018
Examiner: Scheffler, Arnaud

**CATEGORY OF CITED DOCUMENTS**

- **T**: theory or principle underlying the invention
- **E**: earlier patent document, but published on, or after the filing date
- **D**: document cited in the application
- **L**: document cited for other reasons
- **M**: member of the same patent family, corresponding document

**DOCUMENTS CONSIDERED TO BE RELEVANT**

- **X**: particularly relevant if taken alone
- **Y**: particularly relevant if combined with another document of the same category
- **A**: technological background
- **O**: non-written disclosure
- **P**: intermediate document
This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on 06-12-2018

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 2009125079 A1</td>
<td>14-05-2009</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>WO 2008142402 A1</td>
<td>27-11-2008</td>
<td>CN 101687093 A</td>
<td>31-03-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2173435 A1</td>
<td>14-04-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2554159 T3</td>
<td>16-12-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 24495456 A</td>
<td>26-11-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5356563 B2</td>
<td>04-12-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2010527675 A</td>
<td>19-06-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2014012200 A</td>
<td>23-01-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010152817 A1</td>
<td>17-06-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2008142402 A1</td>
<td>27-11-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1868680 A2</td>
<td>26-12-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5027109 B2</td>
<td>19-09-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2008534168 A</td>
<td>28-08-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2006224187 A1</td>
<td>05-10-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2006224222 A1</td>
<td>05-10-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012136411 A1</td>
<td>31-05-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013184798 A1</td>
<td>18-07-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2014214131 A1</td>
<td>31-07-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2006107848 A2</td>
<td>12-10-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003120323 A1</td>
<td>26-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2005107841 A1</td>
<td>19-05-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009062883 A1</td>
<td>05-03-2009</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82.
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

• US 61176868 A [0040]
• US 61151464 A [0043]